Intra-arterial infusion of radiosensitizer (BUdR) combined with hypofractionated irradiation and chemotherapy for primary treatment of osteogenic sarcoma.
Combined modality treatment was given in nine patients of osteogenic sarcoma wherein the tumor was unresectable because of location or amputation was refused. This alternative to massive surgery comprised hypofractionated irradiation, intra-arterial infusion of the radiosensitizer 5'-bromodeoxyuridine (BUdR) and adjuvant systemic chemotherapy. Local control was achieved in seven of the nine patients. Four survived, all without evidence of disease at 6, 7.1, 8.8, and 10.5 years after completion of irradiation. Pulmonary metastases developed in six patients--of whom one survives, following high-dose pulmonary irradiation and additional chemotherapy. Significant soft-tissue injury occurred in five patients. On the basis of our experience, we believe that new approaches using modifications of external beam irradiation with different fractionation schedules or better radiosensitizing compounds may hold promise for patients with non-resectable osteosarcoma.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006229:Hand Dermatoses / Q000139:chemically induced; D006801:Humans; D007261:Infusions, Intra-Arterial; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000098:blood supply / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D011630:Pubic Bone; D011838:Radiation-Sensitizing Agents; D011879:Radiotherapy Dosage
D011838:Radiation-Sensitizing Agents; D001973:Bromodeoxyuridine